A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs Afatinib (Primary)
- Indications Brain cancer
- Focus Adverse reactions
- 24 Oct 2016 Status changed from not yet recruiting to recruiting.
- 23 Oct 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 23 Oct 2016 Planned initiation date changed from 1 Jun 2015 to 1 Nov 2016.